Impact of the rest period between sequential chemotherapy and conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for high-risk myeloid malignancies

IF 3 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Valentin Amenta , Anne Sonet , Elodie Collinge , François Dachy , Cristina Baiana , Benoît Bihin , Xavier Poiré , Carlos Graux
{"title":"Impact of the rest period between sequential chemotherapy and conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for high-risk myeloid malignancies","authors":"Valentin Amenta ,&nbsp;Anne Sonet ,&nbsp;Elodie Collinge ,&nbsp;François Dachy ,&nbsp;Cristina Baiana ,&nbsp;Benoît Bihin ,&nbsp;Xavier Poiré ,&nbsp;Carlos Graux","doi":"10.1016/j.retram.2026.103586","DOIUrl":null,"url":null,"abstract":"<div><div>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for relapsed/refractory acute myeloid leukemia (r/rAML), high-risk myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). Sequential conditioning, combining cytoreductive chemotherapy with reduced-intensity conditioning, was designed to reduce toxicity while preserving efficacy in frail patients. While numerous studies have evaluated different sequential regimens, the impact of rest period duration between the two phases remains unexplored. This bicentric retrospective study analyzed 82 allo-HSCT between 2013 and 2021, in patients with high-risk myeloid malignancies (median age 58 years). Short-bridge-to-transplant regimens (SBTT, n=44) with rest periods of 7 days or less, including the well-known FLAMSA-RIC, were compared to long-bridge-to-transplant regimens (LBTT, n=38) with rest periods longer than 7 days. After a median follow-up of 33 months, rest period duration did not significantly affect progression-free survival (PFS), overall survival, relapse incidence or non-relapse mortality (NRM). Two-year PFS was 35.1% for SBTT versus 57.2% for LBTT (<em>aHR</em> 1.62; <em>P</em>=0.13). However, measurable residual disease-free survival (MRD-FS) was significantly improved with LBTT (<em>aHR</em> 2.15; <em>P</em>=0.02). Despite longer median aplasia, LBTT showed comparable complications and enabled more intensive chemotherapy without increased NRM. LBTT appears feasible and not inferior to SBTT, with a signal of improved MRD control that may reflect better temporal separation and management of treatment-related toxicities, safe delivery of higher-dose or more intensive chemotherapy, and potential leukemic cell-cycle synchronization effects. While center-specific practices and regimen heterogeneity limit definitive conclusions, these hypothesis-generating findings highlight an underexplored dimension of sequential conditioning and warrant further investigation in larger prospective studies.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 2","pages":"Article 103586"},"PeriodicalIF":3.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245231862600022X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for relapsed/refractory acute myeloid leukemia (r/rAML), high-risk myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). Sequential conditioning, combining cytoreductive chemotherapy with reduced-intensity conditioning, was designed to reduce toxicity while preserving efficacy in frail patients. While numerous studies have evaluated different sequential regimens, the impact of rest period duration between the two phases remains unexplored. This bicentric retrospective study analyzed 82 allo-HSCT between 2013 and 2021, in patients with high-risk myeloid malignancies (median age 58 years). Short-bridge-to-transplant regimens (SBTT, n=44) with rest periods of 7 days or less, including the well-known FLAMSA-RIC, were compared to long-bridge-to-transplant regimens (LBTT, n=38) with rest periods longer than 7 days. After a median follow-up of 33 months, rest period duration did not significantly affect progression-free survival (PFS), overall survival, relapse incidence or non-relapse mortality (NRM). Two-year PFS was 35.1% for SBTT versus 57.2% for LBTT (aHR 1.62; P=0.13). However, measurable residual disease-free survival (MRD-FS) was significantly improved with LBTT (aHR 2.15; P=0.02). Despite longer median aplasia, LBTT showed comparable complications and enabled more intensive chemotherapy without increased NRM. LBTT appears feasible and not inferior to SBTT, with a signal of improved MRD control that may reflect better temporal separation and management of treatment-related toxicities, safe delivery of higher-dose or more intensive chemotherapy, and potential leukemic cell-cycle synchronization effects. While center-specific practices and regimen heterogeneity limit definitive conclusions, these hypothesis-generating findings highlight an underexplored dimension of sequential conditioning and warrant further investigation in larger prospective studies.

Abstract Image

高危髓系恶性肿瘤异基因造血干细胞移植前序贯化疗和调理方案间休息时间的影响
同种异体造血干细胞移植(alloo - hsct)仍然是复发/难治性急性髓性白血病(r/rAML)、高风险骨髓增生异常综合征(MDS)和骨髓增生性肿瘤(MPN)的唯一治疗方法。序贯调理,结合细胞减少化疗与降低强度调理,旨在减少毒性,同时保持虚弱患者的疗效。虽然许多研究已经评估了不同的顺序方案,但两个阶段之间休息时间的影响仍未被探索。这项双中心回顾性研究分析了2013年至2021年间82例高风险髓系恶性肿瘤患者(中位年龄58岁)的同种异体造血干细胞移植。将休息时间不超过7天的短桥移植方案(SBTT, n=44)与休息时间超过7天的长桥移植方案(LBTT, n=38)进行比较,其中包括著名的FLAMSA-RIC。中位随访33个月后,休息时间对无进展生存期(PFS)、总生存期、复发率或非复发死亡率(NRM)没有显著影响。SBTT的两年PFS为35.1%,而LBTT为57.2% (aHR 1.62; P=0.13)。然而,LBTT可测量的剩余无病生存期(MRD-FS)显著提高(aHR 2.15; P=0.02)。尽管中位发育不全时间较长,但LBTT显示出类似的并发症,并且可以在不增加NRM的情况下进行更强化的化疗。LBTT似乎是可行的,并不逊于SBTT,其MRD控制改善的信号可能反映了治疗相关毒性的更好的时间分离和管理,更高剂量或更强化的化疗的安全传递,以及潜在的白血病细胞周期同步效应。虽然中心特异性实践和方案异质性限制了明确的结论,但这些产生假设的发现强调了顺序条件作用的未充分探索维度,值得在更大的前瞻性研究中进一步调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Research in Translational Medicine
Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
7.00
自引率
4.90%
发文量
51
审稿时长
45 days
期刊介绍: Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书